Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment - Seite 2

Barry Kostiner, the CEO of Sagaliam, commented, "Our IPF nutraceutical has received strong consumer approval, and we look forward to ramping up our marketing efforts, in parallel with our other nutraceutical products. We are grateful for our relationship with Enzolytics and ETC Marketing to build out the sales, marketing and distribution infrastructure for our expanded portfolio of consumer wellness products. Sagaliam's partnership with Dr. Lachezar Ivanov has resulted in a pipeline of significant consumer nutraceutical products. In addition to IPF Immune, we will be working with Dr. Ivanov to deliver brain detox and liver detox nutraceuticals to the American market, as well as our latest development, IPF immune formulated in tablets and lozenges with Vitamin C."

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC.

While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of its therapeutics in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of its therapeutics in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.

Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.

Company Contact:

Enzolytics, Inc.
1101 Raintree Circle
Allen, Texas 75013
X/Twitter: @enzolyticsinc
[e-mail]

SOURCE: Enzolytics, Inc.

View the original press release on accesswire.com


The Enzolytics Stock at the time of publication of the news with a raise of +7,29 % to 0,005USD on Nasdaq OTC stock exchange (02. Mai 2024, 02:10 Uhr).